This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunotherapy  • Dermatology, Other  • Alert me on articles by topic

Arch Dermatol. 2000;136:774-775.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML
J Am Acad Dematol. 1999;41:1002-1007

The incidence of basal cell carcinomas (BCCs) is very high. Despite the effectiveness of surgical treatments, the development of effective biologic therapies for BCC is important.¹ Beutner et al² performed a randomized, double-blind pilot trial evaluating the safety and efficacy of imiquimod 5% cream vs vehicle in the treatment of BCCs.

A total of 35 patients with BCC participated in their study. The patients were randomized in a 2:1 ratio to receive imiquimod cream in 1 of 5 dosing regimens (7 patients, twice daily; 4, once daily; 4, three times weekly; 5, twice weekly; and 4, once weekly) or vehicle cream (11 patients). Patients continued to receive treatment until 2 weeks after the tumor was clinically cleared as determined . . . [Full Text of this Article]

Editor's Comment